A number of therapies have been developed in the past decades. About two thirds of patients can be seizure free with antiepileptic drugs. 1 Other patients are drug resistant, some of whom are good candidates for epileptic focus resection and become seizure free after surgery. 2 The treatment for drug-resistant patients who are not eligible for resection is still challenging. Traditionally, these patients can receive palliative surgery such as callosotomy and multiple subpial transection, 3, 4 but the long-term outcomes of these procedures are not satisfactory. [5] [6] [7] In the past decades, neuromodulation techniques have been applied in the treatment of epilepsy. Much evidence has been accumulated about the therapeutic effects of vagus nerve stimulation for epilepsy. In contrast to peripheral nerve stimulation, brain stimulation techniques have also been developed for patients with epilepsy recently. Invasive deep brain stimulation (DBS) and noninvasive repetitive transcranial magnetic stimulation (rTMS) as well as transcranial direct current stimulation (tDCS) showed some inspiring results. Here, we will mainly discuss brain stimulation for epilepsy treatment.
DBS for epilepsy
DBS stimulating targets for epilepsy include anterior thalamic nucleus, [8] [9] [10] centromedian thalamic nucleus, 11, 12 subthalamic nucleus, 13, 14 caudate nucleus, 12 and other structures such as cerebellum 15 and hippocampus. 16 The results from case reports, case series, and limited control studies showed DBS is effective in reducing seizure frequency. 17 The results were confirmed by a multicenter randomized double-blind control study of stimulation of the anterior nuclei of thalamus for epilepsy (SANTE). 10 A total of 110 adult patients who had partial seizures with or without secondary generalization at least 6 times per month but no more than 10 times per day were enrolled in this study. The stimulations were given bilaterally to the anterior thalamic nuclei. During the control phase, seizure frequencies in the active treatment group improved 40.4% compared with 14.5% in the control group. When the control group's stimulators were activated at the openlabel phase of the trial, 4 months after implantation, their seizure frequencies also declined. Long-term follow-up of the patients receiving open-label stimulation showed that the benefits were sustained: the median seizure frequency improved by 57% from baseline 25 months after implantation. The number of patients showing 50% or greater improvements in seizure frequency increased and the quality-of-life scores improved during long-term follow-up.
A new strategy for brain stimulation is to deliver stimuli only when seizure onset is detected, a paradigm called responsive neurostimulation. 18 The randomized multicenter trial of responsive neurostimulation enrolled 191 patients with refractory partial seizures with or without secondary generalization. Strip or depth electrodes were implanted adjacent to either one or two previously identified seizure foci and connected to an implanted sensor-stimulator device embedded in the skull. Algorithms were individually tuned to recognize the EEG correlating to seizures. The sensor delivered stimulation to the focus (or foci) as soon as onset of a seizure was recognized. During the blinded phase, seizure frequency decreased by 37.9% compared with baseline in the active-stimulation group and by 17.3% in the control group, suggesting a significant benefit of stimulation. The responsive neurostimulation was approved by the US Food and Drug Administration at the end of 2013.
rTMS for epilepsy
In addition to electrical stimulation, transcranial magnetic stimulation (TMS) opens new horizons in the treatment of epilepsy as a novel therapeutic method. The modern era of TMS began in 1985, when Barker et al 19 developed the first modern TMS device to investigate the human motor cortex. In contrast to the other neurostimulation methodologies, TMS is noninvasive, painless, inexpensive, and has gained increasing interest as an efficient tool to modulate cortical excitability and activity. 20 rTMS can induce long-lasting changes in neural activity 21, 22 and has been applied in recent years to the therapy of various neurological and psychiatric diseases. [23] [24] [25] rTMS could reduce seizures by suppressing abnormal cortical excitability and abnormal spreading activity. In case reports, case series, and clinical trials, most rTMS studies showed favorable effects against epileptic seizure.
21,22,26-30
One randomized control study was designed to evaluate the therapeutic effect of low-frequency rTMS on patients with refractory partial epilepsy. Sixty patients were randomly divided into two groups by stimulation intensity: 90% (group 1) or 20% (group 2) of resting motor threshold (rMT). Following 2 weeks of high-intensity (90% rMT) rTMS treatment, seizures significantly decreased from baseline: 8.9±11.1 seizures per week to 1.8±3.7 per week. But in group 2, stimulation did not show significant antiepileptic effect. The seizure frequency in group 2 was 8.6±10.8 per week at the baseline, and 8.4±10.1 in the follow-up period. Low-frequency high-intensity rTMS (90% rMT) delivered into the epileptogenic zone had a significant antiepileptic effect on patients with refractory partial seizures. 22 In the evaluation of rTMS effects in the management of epilepsy, we should comprehensively consider several factors such as the stimulus frequency, intensity, train duration, coil shape and position, seizure types, antiepileptic drugs, and other heterogeneity during the stimulation treatment.
tDCS for epilepsy
While rTMS can generate strong currents capable to depolarize neurons, tDCS changes the cortical activity by rather weak electric currents. tDCS alters brain activity by influencing ion channels and gradients and hence the resting membrane potential. 31, 32 Prolonged weak currents (1-2 mA) are delivered into the brain tissue transcranially via two large electrodes. The length of the stimulation, strength, and polarity determine the duration and direction of the excitability change. Anodal tDCS leads to brain depolarization (excitation) and cathodal tDCS results in brain hyperpolarization (inhibition). 33 In a recent study, 36 children with focal epilepsy were enrolled, 27 in active and nine in sham groups. All patients tolerated tDCS well without serious adverse events. Active tDCS treatment was associated with significant reductions in epileptic discharge frequency immediately and 24 and 48 hours after tDCS. A statistically significant decrease in seizure frequency was also detected 4 weeks later. The results suggested that cathodal tDCS improved epileptic EEG abnormalities. 34 Another clinical control trial enrolled 19 patients with malformations of cortical development and refractory epilepsy, and these patients underwent one session of tDCS (20 minutes, 1 mA) targeting the epileptogenic focus. tDCS was associated with 64.3% reduction significantly in the number of epileptiform discharges for the active treatment group and 5.8% reduction for the sham treatment group. A trend was noted in the decrease in seizure frequency after active compared with sham treatment (mean seizure frequency decrease of 44.0% for the active treatment group and 11.1% for the sham treatment group). 35 Besides, other studies also displayed favorable results of tDCS in epilepsy treatment. [36] [37] [38] Brain stimulation studies have showed inspiring efficacy in controlling epileptic seizures. Each brain stimulation technique has its own advantages and shortcomings. DBS is an invasive technique, and the device is expensive. Occasionally, the implantation may cause some unexpected complications. Patients' daily life is usually not affected after the implantation of DBS device. rTMS and tDCS are noninvasive, safe, and inexpensive. However, rTMS is not eligible for long-term use, and the device is not portable. tDCS device might be designed for portable use. Different brain stimulation techniques indicated for various patient groups need to be further studied.
For invasive brain stimulation, future work should be focused on search for more effective target and finding eligible parameters. Another direction is to develop new devices, which can be used for simultaneous stimulation of multi-targets. Responsive stimulation device should be reformed to be more effective. Noninvasive stimulation devices should be developed with the capacity to stimulate any part of the brain including deep brain structures and stimulation of multiple brain areas simultaneously or alternatively. Multicenter randomized control trials for different epileptic seizures or specific epilepsy syndromes should be organized to verify the efficacy of the abovementioned stimulation techniques.
